About

Print

 


 

Lipopharma rationally designs and develops potentially transformative synthetic bio-active lipids that specifically interact with key signal-transduction peripheral proteins involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases. Lipopharma arose as an academic spin-off to commercially develop new scientific know-how and applications generated by leading scientists at the University of the Balearic Islands (UIB) in Mallorca, Spain, headed by Prof. Pablo V. Escriba.

 


 

Mission

Lipopharma aims to develop next-generation medicines based on the novel Membrane-Lipid Therapy (MLT) strategy, which targets membrane lipids and/or the structures they form, rather than directly targeting specific cellular proteins. MLT-based drugs specifically interact with and modulate the activity of key signal-transduction response pathways involved in the pathogeny of serious diseases like cancer, CNS, inflammatory or metabolic diseases.

 


 

Vision

Innovative MLT-based drugs will soon become reference treatments worldwide for serious diseases with important medical needs unmet, such as glioblastoma and other aggressive cancer malignancies, as well as neuro-degenerative, metabolic, cardiovascular or inflammatory diseases, providing a safe and efficacious therapeutic alternative that will bring dramatic improvements in the clinical outcome and in the quality of life for an important number of patients with these pathologies

Supported by

DGRDI               

 

© 2019 Lipopharma | legal notice Copyright 2011 Lipopharma - Company. All Rights Reserved.
Joomla 1.7 templates by hostgator coupon and learn how to make a website